Edison, NJ, United States of America

Shilpa Pandit

USPTO Granted Patents = 6 


Average Co-Inventor Count = 11.5

ph-index = 5

Forward Citations = 249(Granted Patents)


Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Shilpa Pandit - Innovator in PCSK9 Antagonists

Introduction

Shilpa Pandit, an accomplished inventor based in Edison, NJ, has made significant contributions to the field of biochemistry, particularly with her focus on PCSK9 antagonists. With a total of six patents to her name, her work is at the forefront of research aimed at improving health outcomes for conditions associated with PCSK9 activity.

Latest Patents

Among her most notable inventions is the patent titled "1B20 PCSK9 Antagonists". This patent discloses antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9), which are crucial for inhibiting PCSK9 function. The technology presented not only includes the antagonists but also nucleic acid encoding these antagonists, vectors, host cells, and associated compositions. Furthermore, methods for producing PCSK9-specific antagonists and their applications for inhibiting PCSK9 function are key elements of this groundbreaking patent. Another notable patent revolves around a "PCSK9 Immunoassay", outlining novel methods to measure circulating PCSK9 levels in biological samples through techniques such as solid-phase immunoassays.

Career Highlights

Shilpa Pandit has had a notable career, with significant tenure at prominent pharmaceutical companies like Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp. Her experience in these esteemed organizations has undoubtedly shaped her innovative research and development capabilities, allowing her to contribute meaningfully to her field.

Collaborations

Working alongside skilled professionals has been a hallmark of Pandit's career. Her collaborations with colleagues such as Jon H. Condra and Ayesha Sitlani reflect a commitment to interdisciplinary teamwork, essential for driving forward complex innovations in the biopharmaceutical industry.

Conclusion

Shilpa Pandit's work exemplifies the spirit of innovation in the medical field. Her patents serve as a testament to her dedication and expertise, aimed at addressing significant health challenges through the development of effective therapeutics for conditions linked to PCSK9. Her contributions will likely continue to influence the direction of research and treatment strategies in the years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…